Business
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
MOUNTAIN VIEW, Calif., March 19, 2026--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics").
About this update from Ignite Limited
[{"type":"text","content":"Busch brings public company leadership and capital markets experience to support Ignite’s next phase of growth","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 19, 2026--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics").","length":374,"tagName":"p"},{"type":"text","content":"Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most likely to work for each patient.","length":339,"tagName":"p"},{"type":"text","content":"Mr. Busch is the Founder, Chairman, and former Chief Executive Officer of Chiron Real Estate Inc. (NYSE: XRN), formerly Global Medical REIT (NYSE: GMRE), a company he founded, bringing public company leadership and capital markets experience to Ignite.","length":252,"tagName":"p"},{"type":"text","content":"As CEO, Mr. Busch will lead Ignite’s commercial expansion and help evaluate strategic growth and financing alternatives as the company advances its business plan.","length":162,"tagName":"p"},{"type":"text","content":""Ignite sits at the intersection of real clinical demand and compelling growth opportunity," said Jeff Busch, Chief Executive Officer of Ignite Proteomics. "We have a commercial-stage platform, Medicare reimbursement, growing clinical validation, and a large addressable market. With approximately 40% of cancer drugs not working for the patients they are prescribed to, Ignite’s assay is designed to help physicians identify the right drug for the right patient at the right time. My focus is disciplined execution — scaling revenue responsibly while building a company capable of generating sustainable profitability. The objective is clear: create durable public market equity value and structured cash flow that benefits Ignite, Aditxt, and its shareholders."","length":783,"tagName":"p"},{"type":"text","content":"&...